Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 4/20 | 0.57 |
| ▸ | HSPA5 | P11021 | 6/20 | 0.52 |
| ▸ | AMD1 | P17707 | 2/20 | 0.48 |
| ▸ | ATG7 | O95352 | 4/20 | 0.48 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6380760 | 0.87 | HSPA8 (0.61) | ADKHSPA5HSPA8RXFP1ADORA3 | |
| SCHEMBL18464494 | 0.83 | ADK (0.51) | ADKHSPA5ATG7HSPA8RXFP1 | |
| SCHEMBL18572077 | 0.80 | PRMT5 (0.73) | — | |
| SCHEMBL18571800 | 0.78 | PRMT5 (0.55) | — | |
| SCHEMBL20419169 | 0.78 | HSPA8 (0.58) | HSPA5HSPA8RXFP1ADORA3 | |
| SCHEMBL20419330 | 0.78 | HSPA8 (0.58) | HSPA5HSPA8RXFP1ADORA3 | |
| SCHEMBL16366019 | 0.77 | HSPA5 (0.66) | ADKHSPA5AMD1HSPA8RXFP1 | |
| SCHEMBL23906717 | 0.77 | HSPA5 (0.48) | ADKHSPA5AMD1ATG7HSPA8 | |
| SCHEMBL17406920 | 0.75 | HSPA8 (0.51) | HSPA5HSPA8RXFP1ADORA3 | |
| SCHEMBL20192483 | 0.75 | HSPA8 (0.51) | HSPA5HSPA8RXFP1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2971010-B1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNATX INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-10258698-B2 | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions | MODERNATX, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-9827332-B2 | Modified polynucleotides for the production of proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170028085-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX INC (US) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170028085-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | ADK 2231/4885HSPA5 1404/4885AMD1 3181/4885 |
| US-10258698-B2 | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions | NSUN2, RNMT, ADAR | ADK 232/4885HSPA5 425/4885AMD1 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.